Trial Profile
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Eftrenonacog alfa (Primary)
- Indications Haemophilia B
- Focus Registrational; Therapeutic Use
- Acronyms PUPs B-LONG
- Sponsors Biogen; Bioverativ
- 14 Dec 2021 Results assessing a descriptive post hoc analysis of spontaneous bleed events in the context of treatment regimen (eg, prophylaxis [PPX] versus on-demand [OD]) in previously untreated participants (PUPs) with hemophilia B treated with extended half-life recombinant factor IX Fc fusion protein (rFIXFc, Alprolix) from the PUPs B-LONG study, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 08 Nov 2021 According to a Sanofi media release, results from this study will be presented as an oral presentation at the American Society of Hematology (ASH) Annual Meeting, 2021.
- 08 Dec 2020 Final results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology